top of page

Initiation of HTL1071 trial triggers $10m payment to Heptares

The first subject has been dosed with immuno-oncology candidate HTL1071 (AZD4635) in a Phase I clinical study, triggering a US$10 million payment toHeptares from AstraZeneca.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page